Please use this identifier to cite or link to this item:
http://hdl.handle.net/10603/584084
Title: | Purification of Protein Charge Variants and Determination of their Potency |
Researcher: | Kumar, Tarun |
Guide(s): | Seshadri, Sriram |
Keywords: | Chromatography Life Sciences Microbiology Monoclonal |
University: | Nirma University |
Completed Date: | 2024 |
Abstract: | Monoclonal antibodies (mAbs) related biological drugs are fastest growing in therapeutic industries across the globe. mAbs were in top best-selling categories of antibody related therapies in 2015. The interest towards mAbs biosimilar development is increasing day by day as there are many patents filed by innovators are supposed to be expire soon. Biosimilars are highly complex and similar biological drugs are developed with different manufacturing processes which are not similar to originator manufacturing process. Due to this, biosimilar product inherently has quality differences in comparison to innovator molecule which may be related to size, charge and glycosylation. Despite these differences they are supposed to demonstrate similar behaviour in safety and efficacy profile to the reference product and these differences should not be clinically meaningful. Charge variants are one of the critical quality attributes and sources of heterogeneity. newlineOmalizumab (Xolair) is a humanized monoclonal antibody derived by recombinant DNA technology. It binds specifically to immunoglobulin E (IgE) which plays a major role in allergic reaction. In this study, biosimilar product of Xolair was expressed in mammalian cell culture process in laboratory to isolate charge variants (acidic and basic) and main peak. Isolated charge variants were purified with preparative cation exchange chromatography technique and characterized with different analytical tools includes size exclusion chromatography (SEC-HPLC) and cation exchange chromatography (CEX-HPLC). Purity of acidic variants, main peak and basic variants was more than 90% estimated by SEC-HPLC and CEX-HPLC. newlineHighly purified charge variants of Xolair biosimilar were also assessed for their impact on in-vitro potency and stability at different thermal stress conditions (2-8 °C and -20 °C). The study data indicates purified charge variants (gt 90%) have no impact on in-vitro potency and are stable at different thermal stress conditions up to a week. newlineThis is not only one factor rela |
Pagination: | |
URI: | http://hdl.handle.net/10603/584084 |
Appears in Departments: | Institute of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
01_title .pdf | Attached File | 162.74 kB | Adobe PDF | View/Open |
02_prelim pages.pdf | 391.88 kB | Adobe PDF | View/Open | |
03_content.pdf | 134.24 kB | Adobe PDF | View/Open | |
04_abstract.pdf | 34.09 kB | Adobe PDF | View/Open | |
05_chapter1.pdf | 327.57 kB | Adobe PDF | View/Open | |
06_chapter2.pdf | 438.75 kB | Adobe PDF | View/Open | |
07_chapter3.pdf | 185.86 kB | Adobe PDF | View/Open | |
08_chapter4.pdf | 796.72 kB | Adobe PDF | View/Open | |
09_chapter5.pdf | 83.17 kB | Adobe PDF | View/Open | |
10_annexures.pdf | 480.56 kB | Adobe PDF | View/Open | |
80_recommendation.pdf | 192.25 kB | Adobe PDF | View/Open | |
certificate.pdf | 201.26 kB | Adobe PDF | View/Open |
Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Altmetric Badge: